Target type: biologicalprocess
Any biological process involved in the maintenance of the steady-state number of hepatocytes within a population of cells. Hepatocytes are specialized epithelial cells of the liver that are organized into interconnected plates called lobules. [CL:0000182, GOC:nhn, PMID:19878874]
Hepatocyte homeostasis is a complex and tightly regulated process that ensures the proper functioning of the liver, a vital organ responsible for a wide range of metabolic, detoxification, and synthetic processes. It involves the maintenance of a stable population of hepatocytes, the primary cell type in the liver, through a delicate balance of cell proliferation, differentiation, and death.
Hepatocyte homeostasis is governed by a intricate interplay of intrinsic and extrinsic factors:
**Intrinsic Factors:**
* **Cell Cycle Regulation:** Hepatocytes possess a remarkable ability to regenerate after injury. This regenerative capacity is tightly controlled by cell cycle regulators like cyclins, cyclin-dependent kinases (CDKs), and their inhibitors. These molecules orchestrate the progression through different phases of the cell cycle, ensuring proper DNA replication and cell division.
* **Growth Factors and Cytokines:** Hepatocyte growth factor (HGF), epidermal growth factor (EGF), and transforming growth factor-alpha (TGF-α) are key growth factors that stimulate hepatocyte proliferation. Cytokines, such as interleukin-6 (IL-6), play a role in coordinating the regenerative response and influencing the balance between cell proliferation and death.
* **Transcription Factors:** Transcription factors, such as nuclear factor-κB (NF-κB) and STAT3, regulate the expression of genes involved in hepatocyte survival, proliferation, and differentiation.
**Extrinsic Factors:**
* **Nutrient Availability:** The liver is a central hub for metabolism, and the availability of nutrients like glucose, amino acids, and fatty acids influences hepatocyte homeostasis.
* **Hormonal Signals:** Hormones like insulin, glucagon, and thyroid hormones play a crucial role in regulating hepatocyte metabolism and function, indirectly influencing homeostasis.
* **Extracellular Matrix:** The extracellular matrix surrounding hepatocytes provides structural support, regulates cell adhesion, and influences cell signaling pathways involved in homeostasis.
**Key Processes in Hepatocyte Homeostasis:**
* **Cell Proliferation:** Following injury or loss of hepatocytes, the remaining cells receive signals to enter the cell cycle and proliferate, replacing the lost cells.
* **Differentiation:** During regeneration, newly formed hepatocytes undergo differentiation to acquire the mature functions of hepatocytes, including metabolic processing, detoxification, and protein synthesis.
* **Apoptosis:** Programmed cell death, or apoptosis, plays a role in eliminating damaged or senescent hepatocytes, ensuring the maintenance of a healthy population.
* **Cell Survival:** Hepatocytes possess mechanisms to protect themselves from damage and promote survival, such as the activation of anti-apoptotic pathways and the expression of stress response genes.
**Disruption of Hepatocyte Homeostasis:**
Imbalances in hepatocyte homeostasis can lead to various liver diseases:
* **Liver Cirrhosis:** Chronic liver injury, often caused by viral hepatitis, alcohol abuse, or fatty liver disease, can lead to the formation of scar tissue, disrupting normal liver structure and function.
* **Hepatocellular Carcinoma (HCC):** Uncontrolled proliferation of hepatocytes can lead to the development of liver cancer.
* **Hepatic Steatosis (Fatty Liver):** Accumulation of fat in hepatocytes can impair liver function and contribute to other liver diseases.
**Therapeutic Approaches:**
* **Regenerative Therapies:** Stem cell transplantation and gene therapy are being investigated as potential strategies for regenerating damaged liver tissue and restoring hepatocyte homeostasis.
* **Pharmacological Treatments:** Drugs targeting specific pathways involved in hepatocyte homeostasis are being developed to treat liver diseases.
* **Lifestyle Modifications:** Changes in diet, exercise, and alcohol consumption can help maintain liver health and prevent disruptions in hepatocyte homeostasis.
Hepatocyte homeostasis is a dynamic and complex process, essential for maintaining liver function and overall health. Understanding the intricate mechanisms involved is crucial for developing effective therapies for liver diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Histone-lysine N-methyltransferase EZH2 | A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
3-deazaneplanocin | 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist | ||
tanshinone | tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent | abietane diterpenoid | anticoronaviral agent |
przewaquinone d | przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D | ||
tanshinone ii a | tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source | abietane diterpenoid | |
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
epz005687 | EPZ005687: inhibits EZH2 protein; structure in first source | indazoles | |
epz-6438 | tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity | ||
gsk-2816126 | GSK-2816126: inhibits EZH2 methyltransferase; structure in first source | piperazines; pyridines | |
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | (R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitor | indolecarboxamide |